The stock of Caredx Inc (CDNA) has seen a -3.33% decrease in the past week, with a -23.66% drop in the past month, and a -24.01% decrease in the past quarter. The volatility ratio for the week is 5.75%, and the volatility levels for the past 30 days are at 6.53% for CDNA. The simple moving average for the past 20 days is -12.27% for CDNA’s stock, with a -19.87% simple moving average for the past 200 days.
Is It Worth Investing in Caredx Inc (NASDAQ: CDNA) Right Now?
Caredx Inc (NASDAQ: CDNA) has a price-to-earnings ratio that is above its average at 17.98x. The stock has a 36-month beta value of 2.17. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for CDNA is 51.92M, and at present, short sellers hold a 9.97% of that float. On March 14, 2025, the average trading volume of CDNA was 879.56K shares.
CDNA) stock’s latest price update
The stock of Caredx Inc (NASDAQ: CDNA) has increased by 3.68 when compared to last closing price of 17.64.Despite this, the company has seen a loss of -3.33% in its stock price over the last five trading days. businesswire.com reported 2025-03-11 that BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that AlloSure® is now commercially available for pediatric heart transplant patients of all ages and patients who have received a simultaneous pancreas-kidney (SPK) transplant. Both indicatio.
Analysts’ Opinion of CDNA
Many brokerage firms have already submitted their reports for CDNA stocks, with Wells Fargo repeating the rating for CDNA by listing it as a “Equal Weight.” The predicted price for CDNA in the upcoming period, according to Wells Fargo is $24 based on the research report published on January 15, 2025 of the current year 2025.
Wells Fargo, on the other hand, stated in their research note that they expect to see CDNA reach a price target of $28. The rating they have provided for CDNA stocks is “Underweight” according to the report published on August 28th, 2024.
BTIG Research gave a rating of “Buy” to CDNA, setting the target price at $40 in the report published on August 19th of the previous year.
CDNA Trading at -17.37% from the 50-Day Moving Average
After a stumble in the market that brought CDNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.50% of loss for the given period.
Volatility was left at 6.53%, however, over the last 30 days, the volatility rate increased by 5.75%, as shares sank -26.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.12% lower at present.
During the last 5 trading sessions, CDNA fell by -3.86%, which changed the moving average for the period of 200-days by +14.12% in comparison to the 20-day moving average, which settled at $20.84. In addition, Caredx Inc saw -14.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDNA starting from Bickerstaff George, who sale 20,000 shares at the price of $18.36 back on Mar 10 ’25. After this action, Bickerstaff George now owns 103,027 shares of Caredx Inc, valued at $367,102 using the latest closing price.
GEORGE W BICKERSTAFF, the Director of Caredx Inc, proposed sale 20,000 shares at $18.36 during a trade that took place back on Mar 10 ’25, which means that GEORGE W BICKERSTAFF is holding shares at $367,102 based on the most recent closing price.
Stock Fundamentals for CDNA
Current profitability levels for the company are sitting at:
- 0.12 for the present operating margin
- 0.67 for the gross margin
The net margin for Caredx Inc stands at 0.16. The total capital return value is set at 0.1. Equity return is now at value 19.46, with 12.57 for asset returns.
Based on Caredx Inc (CDNA), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at 1.71.
Currently, EBITDA for the company is -33.99 million with net debt to EBITDA at -1.41. When we switch over and look at the enterprise to sales, we see a ratio of 2.78. The receivables turnover for the company is 5.17for trailing twelve months and the total asset turnover is 0.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.94.
Conclusion
To sum up, Caredx Inc (CDNA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
